Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma Meeting Abstract
| Authors: | Pal, S. K.; Tannir, N. M.; Grell, P.; Gao, X.; Kotecha, R. R.; Picus, J.; De Braud, F. G.; Takahashi, S.; Wong, A.; Suarez, C.; Otero, J. A.; Kundamal, N.; Yang, X.; Sharaby, S.; Roy, M.; Barzaghi-Rinaudo, P.; Albiges, L. |
| Abstract Title: | Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401160 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.4513 |
| Notes: | Meeting Abstract: 4513 -- Source: Wos |
